Tag : FLT3

CONFERENCE UPDATE

Gilteritinib continues to improve OS in R/R FLT3-mutated AML at 3-year follow-up of the Asian-centric phase 3 COMMODORE trial
Relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) is associated with a poor prognosis.1 While global trials have demonstrated that gilteritinib offers superior survival benefits and a favorable safety profile compared to standard chemotherapy, long-term randomized